Matches in Wikidata for { <http://www.wikidata.org/entity/Q66064950> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- Q66064950 description "clinical trial" @default.
- Q66064950 description "ensayu clínicu" @default.
- Q66064950 description "klinisch onderzoek" @default.
- Q66064950 description "клінічне випробування" @default.
- Q66064950 name "A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis" @default.
- Q66064950 name "A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis" @default.
- Q66064950 type Item @default.
- Q66064950 label "A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis" @default.
- Q66064950 label "A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis" @default.
- Q66064950 prefLabel "A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis" @default.
- Q66064950 prefLabel "A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis" @default.
- Q66064950 P1050 Q66064950-80A5E8A6-3694-4C56-8DE7-BBD3E8710909 @default.
- Q66064950 P1050 Q66064950-D141BC69-351B-48C9-9924-B1049F6E00E8 @default.
- Q66064950 P1132 Q66064950-0CBE93EC-4C1D-462F-B971-AEA615124F8A @default.
- Q66064950 P1476 Q66064950-638BF415-0061-4B4D-B1A2-924CA9FDDDD5 @default.
- Q66064950 P17 Q66064950-AE3FD426-3A66-4136-9FAA-9613E8FF140C @default.
- Q66064950 P2899 Q66064950-25A66515-6906-41AC-A439-C59BFA7CDA5F @default.
- Q66064950 P3098 Q66064950-BDD25058-0715-498D-92EF-291DAF3C5878 @default.
- Q66064950 P31 Q66064950-32A05A71-2998-4F4D-B9B6-B6E2B55FE818 @default.
- Q66064950 P4135 Q66064950-C8B8E2D1-5E22-4B5C-A06D-6CE027568E63 @default.
- Q66064950 P580 Q66064950-3F7F4720-7968-46CB-AAB5-334D115B6419 @default.
- Q66064950 P582 Q66064950-E778C58F-3A75-4325-A584-0DBC0372AEA0 @default.
- Q66064950 P6099 Q66064950-91091195-04B2-4CEC-A035-00909F0B4B2E @default.
- Q66064950 P6153 Q66064950-269C7B3A-9B91-4A64-AA8D-8EDC353B4BF6 @default.
- Q66064950 P6153 Q66064950-44DA4116-5DF2-4833-8751-C93F708B7869 @default.
- Q66064950 P6153 Q66064950-62734167-FFC6-438E-9863-61837CCBB173 @default.
- Q66064950 P6153 Q66064950-80CBC07A-06F2-4AF5-A16E-BC1AF7707BD0 @default.
- Q66064950 P6153 Q66064950-F7CF321A-5036-4B32-B726-4A2147B017F8 @default.
- Q66064950 P8363 Q66064950-A43F8D16-1A65-4448-B30B-12C3CE14FC9F @default.
- Q66064950 P859 Q66064950-68A69A10-74EA-49B1-BF89-2D0AA753768B @default.
- Q66064950 P1050 Q140067 @default.
- Q66064950 P1050 Q8277 @default.
- Q66064950 P1132 "+135" @default.
- Q66064950 P1476 "A Phase Ib, Open-Label, Multicenter Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis" @default.
- Q66064950 P17 Q30 @default.
- Q66064950 P2899 "+18" @default.
- Q66064950 P3098 "NCT03972306" @default.
- Q66064950 P31 Q30612 @default.
- Q66064950 P4135 "+65" @default.
- Q66064950 P580 "2019-07-05T00:00:00Z" @default.
- Q66064950 P582 "2021-02-15T00:00:00Z" @default.
- Q66064950 P6099 Q5452194 @default.
- Q66064950 P6153 Q235034 @default.
- Q66064950 P6153 Q2415975 @default.
- Q66064950 P6153 Q30270303 @default.
- Q66064950 P6153 Q333886 @default.
- Q66064950 P6153 Q49117 @default.
- Q66064950 P8363 Q78089383 @default.
- Q66064950 P859 Q212646 @default.